Merck, Ridgeback seek FDA approval for COVID pill

Monday, 11. October 2021 12:08

Merck & Co. Inc. and Ridgeback Biotherapeutics unveiled on Monday that they are seeking emergency use authorization from the United States Food and Drug Administration for their oral COVID-19 pill.

The move comes following the positive results from the Phase 3 clinical trial for the drug molnupiravir. Moreover, the pharmaceutical companies also noted that they are working with other regulatory agencies worldwide and plan to submit further applications for the drug's use in the coming months.

Merck CEO Robert Davis commented on the development: "The extraordinary impact of this pandemic demands that we move with unprecedented urgency, and that is what our teams have done by submitting this application for molnupiravir to the FDA within 10 days of receiving the data."

Related Links: Merck KGaA
Author:
Baha Breaking the News (BBN) / OL